MedPath

Proveca Pharma Ltd.

🇮🇪Ireland
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:1
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 4:1

Drug Approvals

3

EMA:2
CIMA_AEMPS:1

Drug Approvals

Aqumeldi

Authorization Status
Authorised
Approval Date
Nov 15, 2023
EMA

Sialanar

Authorization Status
Authorised
Approval Date
Sep 15, 2016
EMA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 4
1 (50.0%)

Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,

Phase 4
Conditions
Sialorrhea
Neurodevelopmental Disorders
Interventions
Other: Placebo
Other: Oral Rehabilitation
First Posted Date
2021-05-05
Last Posted Date
2022-07-08
Lead Sponsor
Proveca Pharma Limited
Target Recruit Count
80
Registration Number
NCT04873115
Locations
🇫🇷

CHU Lille, Lille, France

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.